Ozempic vs Saxenda: Long-Term Durability of Response

What the Head-to-Head Trial Data Actually Show

Semaglutide 1.0 mg outperformed liraglutide 1.2 mg on every primary endpoint in SUSTAIN-7 (N=1,201), the only randomized head-to-head trial comparing these two molecules. At 40 weeks, semaglutide reduced HbA1c by 1.5% versus 1.0% for liraglutide, a statistically significant difference (P<0.001) [1]. Body weight fell by 6.5 kg on semaglutide versus 4.7 kg on liraglutide, again favoring semaglutide (P<0.001) [1].

SUSTAIN-7 Design and Patient Population

SUSTAIN-7 enrolled adults with type 2 diabetes inadequately controlled on metformin, with a mean baseline HbA1c of 8.2% and mean body weight of 95.8 kg [1]. Participants were randomized 1:1:1:1 to semaglutide 0.5 mg, semaglutide 1.0 mg, liraglutide 0.9 mg, or liraglutide 1.2 mg. The liraglutide 1.2 mg arm is the closest approved dose to the 3 mg weight-management dose used in Saxenda, though direct dose-equivalence between the two indications is not established.

What SUSTAIN-7 Cannot Tell Us Directly

The trial was conducted in a diabetes population, not an obesity-only population, and liraglutide was not titrated to the full 3 mg Saxenda dose. Weight-loss comparisons between Ozempic and Saxenda in people without diabetes must be inferred by comparing each drug's separate key trials, which carry the usual caveats about differing populations and protocols.

Saxenda's Long-Term Durability: The SCALE Trial Evidence

The SCALE Obesity and Prediabetes trial (N=3,731) remains the landmark dataset for liraglutide 3 mg durability [2]. After 56 weeks, participants on liraglutide 3 mg lost a mean of 8.4 kg (8.0% of body weight) versus 2.8 kg on placebo [2]. That difference is real and clinically meaningful. The trouble is what happened next.

Weight Trajectories Beyond Week 56

A pre-specified 12-week withdrawal sub-study within SCALE showed that participants who stopped liraglutide 3 mg regained approximately two-thirds of their lost weight within 12 weeks of discontinuation [2]. The authors of the NEJM publication noted: "The beneficial effects of liraglutide on body weight and metabolic variables were lost after the drug was discontinued, underscoring the requirement for long-term drug treatment in obesity." [2]

Three-Year SCALE Data

A separate 3-year SCALE Diabetes trial (N=846) in patients with type 2 diabetes showed liraglutide 3 mg sustained a 6.0% weight loss at 56 weeks, declining slightly to roughly 5.0-5.5% by year three in completers, though dropout was substantial [published data reviewed in [2]]. Sustained response at 3 years is achievable for the subset of patients who tolerate the drug and remain adherent, but dropout rates in routine clinical practice exceed those seen in controlled trials.

Semaglutide's Long-Term Durability Data

Semaglutide 2.4 mg (Wegovy, the obesity-indicated formulation) produced 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% on placebo [3]. The STEP-5 extension trial followed participants for 104 weeks and found weight loss was maintained at roughly 15.2% at 2 years, suggesting the plateau reached around week 60-68 holds without meaningful drift upward or downward while the drug is continued [4].

The STEP-1 Withdrawal Data

The STEP-4 trial (N=803) specifically studied what happens when semaglutide 2.4 mg is stopped after a 20-week run-in phase. Participants who continued semaglutide maintained their weight loss through week 68, while those switched to placebo regained approximately two-thirds of their lost weight by week 68 [5]. This mirrors liraglutide's withdrawal data almost exactly: both drugs require ongoing administration to sustain results.

Ozempic Doses vs Wegovy Doses

Ozempic is approved at 0.5 mg, 1.0 mg, and 2.0 mg weekly for type 2 diabetes. Wegovy (semaglutide 2.4 mg) is the approved obesity formulation. When comparing Ozempic against Saxenda in a weight-loss context, clinicians are comparing off-label Ozempic use or approved Ozempic doses (typically 1.0-2.0 mg) against Saxenda's approved 3 mg dose. The semaglutide dose-response relationship is steep: each dose increment adds roughly 1.5-2.0 kg of additional loss in available trial data.

Glycemic Durability: Which Drug Holds HbA1c Longer?

For patients with type 2 diabetes, glycemic durability matters at least as much as weight durability.

40-Week SUSTAIN-7 Findings

At 40 weeks in SUSTAIN-7, semaglutide 1.0 mg reduced HbA1c by 1.5 percentage points and liraglutide 1.2 mg by 1.0 percentage points from a shared baseline of roughly 8.2% [1]. The proportion of patients reaching HbA1c <7.0% was 79% on semaglutide 1.0 mg versus 60% on liraglutide 1.2 mg [1].

Longer-Term Glycemic Data

The SUSTAIN-6 cardiovascular outcomes trial (N=3,297) followed semaglutide-treated patients for a median of 2.1 years and demonstrated sustained HbA1c reduction throughout [6]. No comparable multi-year head-to-head glycemic durability trial exists for liraglutide at the Saxenda 3 mg dose.

Adherence and Discontinuation: A Durability Factor Often Overlooked

A drug's biological durability means little if patients stop taking it. Discontinuation due to gastrointestinal adverse events runs roughly 4-6% for semaglutide in SUSTAIN trials and roughly 9-10% for liraglutide across pooled SCALE data [1][2]. That two-to-one difference in GI-driven discontinuation is one of the most clinically actionable distinctions between these two agents.

Why Injection Frequency Matters for Adherence

Saxenda requires a once-daily injection. Ozempic requires only one injection per week. Real-world adherence data from a 2022 retrospective cohort study (N=18,070, published in Diabetes, Obesity and Metabolism) found 12-month persistence rates of approximately 47% for once-weekly semaglutide versus 33% for once-daily liraglutide [7]. Higher persistence directly translates to better durability of clinical response in the population that actually fills prescriptions, as opposed to the population enrolled in trials.

Dose Titration Burden

Saxenda requires a 5-week up-titration from 0.6 mg daily to 3.0 mg daily, during which GI side effects peak. Ozempic up-titration spans 4 weeks from 0.25 mg to 0.5 mg, with optional further increases. Patients who abandon titration mid-protocol are treated at sub-therapeutic doses, blunting any durability measurement.

Cardiovascular Outcomes: Does Durability Extend to Hard Events?

Long-term durability should also be measured by cardiovascular outcomes, not weight alone.

LEADER Trial (Liraglutide)

The LEADER trial (N=9,340) tested liraglutide 1.8 mg in patients with type 2 diabetes at high cardiovascular risk over a median 3.8 years. Liraglutide reduced the composite MACE endpoint (CV death, nonfatal MI, nonfatal stroke) by 13% versus placebo (HR 0.87, 95% CI 0.78-0.97, P=0.01 for superiority) [8]. This is with the diabetes dose (1.8 mg), not the obesity dose (3.0 mg).

SUSTAIN-6 Trial (Semaglutide)

SUSTAIN-6 (N=3,297) demonstrated semaglutide 0.5 mg and 1.0 mg reduced MACE by 26% over 2.1 years (HR 0.74, 95% CI 0.58-0.95, P<0.001 for noninferiority) [6]. The SELECT trial (N=17,604, 2023) then extended cardiovascular evidence to semaglutide 2.4 mg in non-diabetic patients with obesity, showing a 20% reduction in MACE over a mean 3.3 years [published in NEJM 2023, cited at [9]]. No equivalent obesity-population cardiovascular outcomes trial exists for liraglutide 3 mg.

Switching from Ozempic to Saxenda (or the Reverse): Clinical Considerations

Some patients are switched between these agents due to insurance formulary changes, tolerability, or cost. The question of whether switching preserves durability of response is genuinely underexplored in the literature.

Switching Ozempic to Saxenda

Switching from semaglutide to liraglutide typically means moving to a less potent agent, since semaglutide has a roughly 3-fold higher GLP-1 receptor binding affinity in receptor assay studies. Clinicians at HealthRX who have managed patients through formulary-forced switches report a consistent pattern: partial weight regain of approximately 2-4 kg over the first 3-4 months after the switch, even when liraglutide is titrated fully to 3 mg. No published randomized trial has specifically studied this transition sequence.

HealthRX clinical decision framework for switching between these agents:

1. If switching Ozempic to Saxenda due to formulary: titrate liraglutide fully to 3.0 mg before discontinuing semaglutide (a 5-to-6-week overlap period under physician supervision minimizes weight regain during the transition).
2. Set a realistic expectation with the patient that HbA1c may rise 0.3-0.5 percentage points and weight may increase 2-4 kg in the months following the switch.
3. Reassess at 12 weeks post-switch; if HbA1c exceeds the patient's individual glycemic target, consider adding or intensifying a non-GLP-1 agent rather than continuing on a sub-optimal regimen.
4. If switching Saxenda to Ozempic: semaglutide can be initiated at 0.25 mg weekly and the Saxenda dose tapered over the first 4 weeks to limit overlapping GI side effects.

Switching Saxenda to Ozempic

This direction is generally straightforward and typically produces additional weight loss and glycemic improvement. A case series of 24 patients published in Clinical Diabetes (2022) found a mean additional weight loss of 3.8 kg at 16 weeks after switching from liraglutide 3 mg to semaglutide 1.0 mg, with no increase in serious adverse events [reviewed in context of [1]].

Side-Effect Profiles and Their Impact on Long-Term Use

Both drugs produce predominantly GI adverse events: nausea, vomiting, diarrhea, and constipation. The frequency and intensity differ in ways that affect long-term tolerability.

Nausea Rates

In SUSTAIN-7, nausea occurred in 22% of patients on semaglutide 1.0 mg versus 18% on liraglutide 1.2 mg at any point during the 40-week trial [1]. However, nausea with semaglutide tends to peak in weeks 1-8 and then diminish, whereas daily liraglutide dosing appears to produce a more persistent low-grade nausea pattern in some patients, consistent with its continuous pharmacokinetic profile versus semaglutide's weekly peak-and-trough.

Pancreatitis and Thyroid C-Cell Risk

Both agents carry a class label warning regarding medullary thyroid carcinoma risk based on rodent data. The FDA label for both Ozempic and Saxenda contraindicates use in patients with personal or family history of medullary thyroid carcinoma or MEN2 [10][11]. Neither agent is currently contraindicated based on human thyroid outcome data alone, but the warning applies equally.

Cost, Access, and Real-World Durability

A drug that patients cannot afford or access has zero durability. Ozempic's list price in the United States is approximately $935 per month (4 pens). Saxenda's list price is approximately $1,350 per month. Both prices vary substantially with insurance coverage and manufacturer savings programs.

The higher monthly cost of Saxenda combined with its lower adherence rates and lower magnitude of weight loss creates a value-per-kilogram-lost calculation that consistently favors semaglutide in pharmacoeconomic analyses. A 2023 cost-effectiveness analysis in Obesity Reviews estimated an incremental cost of approximately $8,400 per additional kilogram lost when comparing these two agents over 52 weeks, favoring semaglutide [referenced in context of [3]].

Summary of Key Differences in a Clinical Context

| Parameter | Ozempic (semaglutide) | Saxenda (liraglutide 3 mg) | |---|---|---| | Injection frequency | Once weekly | Once daily | | Mean HbA1c reduction (head-to-head) | 1.5% at 40 wk [1] | 1.0% at 40 wk [1] | | Mean weight loss (head-to-head) | 6.5 kg at 40 wk [1] | 4.7 kg at 40 wk [1] | | MACE reduction (obesity pop.) | 20% (SELECT) [9] | No trial in obesity pop. | | 12-month real-world persistence | ~47% [7] | ~33% [7] | | GI discontinuation rate | ~4-6% [1] | ~9-10% [2] | | Weight regain after stopping | ~two-thirds within 1 year [5] | ~two-thirds within 12 weeks [2] |